A Phase 2 interventional study of CAR-T in Multiple Myeloma Refractory and Multiple Myeloma in Relapse, sponsored by Dr. Zaineb Akram. Recruiting at 2 sites in Pakistan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Dr. Zaineb Akram · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The treatment options for multiple myeloma have evolved significantly over the years, providing patients with a range of therapies tailored to their specific circumstances. The choice of treatment often hinges on various factors, including the aggressiveness of the disease, individual prognostic indicators like genetic markers, the overall physical condition of the patient, and any pre-existing health issues that may affect treatment decisions. Current therapeutic strategies include several classes of drugs, each working through different mechanisms. Proteasome inhibitors (PIs) disrupt the protein degradation process within myeloma cells, thereby promoting their death. Immunomodulatory drugs (IMiDs) modulate the immune system and inhibit tumor growth by enhancing the body's natural anti-cancer responses. Monoclonal antibodies specifically target cancer cells, marking them for destruction by the immune system. In cases where patients are eligible, autologous stem cell transplantation remains a viable option, offering the potential for long-term remission by replacing damaged bone marrow with healthy stem cells from the patient's own body.
Despite these advancements, multiple myeloma continues to present significant challenges, as it often recurs even after initial successful treatment and remains an incurable disease. This highlights the urgent need for innovative therapeutic strategies that can effectively address resistance to existing treatments, ultimately aiming to improve patient outcomes and survival rates.
Multiple myeloma is characterized by the synthesis of monoclonal immunoglobulin (Ig) proteins or their fragments, known as M proteins, which have lost their biological functionality. (Kyle \& Rajkumar, 2008; Palumbo \& Anderson, 2011).
The proliferation of multiple myeloma cells results in the gradual displacement of normal bone marrow hematopoietic precursors, which are essential for the production of blood cells. This displacement not only hampers the normal hematopoiesis process but also leads to an overproduction of M-proteins, which can have detrimental effects on the body's systems. Key characteristics of multiple myeloma include osteolytic lesions (areas of bone destruction that can lead to fractures and significant pain). Patients often experience anemia due to the impaired production of red blood cells, making them more prone to fatigue and weakness. Moreover, the disease can significantly increase susceptibility to infections, as the immune system becomes compromised. Additional complications include hypercalcemia (characterized by abnormally high calcium levels in the blood), which can lead to nausea and confusion. Renal insufficiency or failure is another serious consequence, often arising from the effects of M-proteins on kidney function. Lastly, neurological complications can occur, manifesting as various symptoms ranging from peripheral neuropathy to more severe neurological deficits. Collectively, these manifestations highlight the complex and multifaceted impact of multiple myeloma on patients' health. (Korde et al., 2011; Palumbo \& Anderson, 2011) In the year 2022, a total of 187,952 cases of Multiple Myeloma (MM) were documented across the globe, representing approximately 0.94% of all cancer cases reported internationally. This hematological malignancy exhibits notable geographical variations in its incidence rates. Notably, Asia accounted for the highest number of cases, with 73,870 reported instances, which corresponds to 39.3% of the global total. Europe and Northern America followed, with 50,092 cases (26.7%) and 37,050 cases (19.7%), respectively. Among the countries in the Eastern Mediterranean Region (EMRO), Pakistan has reported the highest rates of incidence (25.3%) and mortality (26.3%) for Multiple Myeloma (MM). In Pakistan, there were 1,846 new cases of Multiple Myeloma and 1,616 deaths attributed to this disease. These statistics highlight the clinical and epidemiological importance of MM both regionally and globally. They emphasize the ongoing need for research and healthcare strategies aimed at improving patient outcomes and understanding the factors contributing to the incidence and mortality of this complex disease. (Global Cancer Observatory, 2024).
Figure 01: Absolute numbers, Incidence of Multiple Myeloma in EMRO, both sexes, in 2022 (Global Cancer Observatory, 2024).
Figure 02: Absolute numbers, Mortality rate due to Multiple Myeloma in EMRO, both sexes, in 2022 (Global Cancer Observatory, 2024).
The treatment options for multiple myeloma have evolved significantly over the years, providing patients with a range of therapies tailored to their specific circumstances. The choice of treatment often hinges on various factors, including the aggressiveness of the disease, individual prognostic indicators like genetic markers, the overall physical condition of the patient, and any pre-existing health issues that may affect treatment decisions. Current therapeutic strategies include several classes of drugs, each working through different mechanisms. Proteasome inhibitors (PIs) disrupt the protein degradation process within myeloma cells, thereby promoting their death. Immunomodulatory drugs (IMiDs) modulate the immune system and inhibit tumor growth by enhancing the body's natural anti-cancer responses. Monoclonal antibodies specifically target cancer cells, marking them for destruction by the immune system. In cases where patients are eligible, autologous stem cell transplantation remains a viable option, offering the potential for long-term remission by replacing damaged bone marrow with healthy stem cells from the patient's own body.
Despite these advancements, multiple myeloma continues to present significant challenges, as it often recurs even after initial successful treatment and remains an incurable disease. This highlights the urgent need for innovative therapeutic strategies that can effectively address resistance to existing treatments, ultimately aiming to improve patient outcomes and survival rates.
4.2. BCMA B Cell Maturation Antigen (BCMA), also known as TNFRSF17, is a vital membrane protein intricately involved in the survival and proliferation of B lineage cells. This essential protein interacts with two key ligands: the proliferation-inducing ligand (APRIL) and the B-cell activating factor (BAFF). Both ligands play a crucial role in promoting the growth and longevity of plasma cells, which are critical components of the immune system (Tai \& Anderson, 2015).
Recent research has highlighted the significant therapeutic potential of targeting BCMA as a treatment strategy for multiple myeloma (MM). Advances in this domain have led to the development of innovative BCMA-targeted therapies, including engineered CAR T-cell therapy and bispecific T-cell engagers. These groundbreaking approaches have demonstrated impressive efficacy in early-phase clinical trials, resulting in durable responses among patients with advanced, heavily pre-treated MM (Patel et al., 2004; Avery et al., 2003).
4.3. CAR-T Therapy The Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a groundbreaking advancement in the field of immunotherapy, specifically designed to harness the patient's own immune system to target and eliminate cancer cells. This innovative approach involves genetically modifying a patient's T cells so they can express a chimeric antigen receptor that specifically recognizes antigens present on the tumor cells.
Mechanism of Action The CAR-T process typically begins with the collection of T cells from the patient through a procedure known as apheresis. The collected T cells are then genetically engineered in a laboratory setting to produce Chimeric Antigen Receptors (CARs) that can recognize specific cancer markers, such as CD19, in B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma. Once engineered, these CAR-T cells are expanded in number and subsequently infused back into the patient. Upon reintroduction, the CAR-T cells patrol the body for cancer cells expressing the target antigen, initiating an immune response that can lead to cellular lysis of the malignant cells (June et al., 2018).
Clinical Efficacy CAR-T therapy has shown remarkable success, particularly in hematologic malignancies. For example, studies have reported overall response rates (ORR) exceeding 80% in patients with relapsed or refractory ALL after treatment with CAR-T cells targeting CD19 (Kymriah®) (Schuster et al., 2019). Similarly, in patients with large B-cell lymphoma, the CAR-T product axicabtagene ciloleucel (Yescarta®) also demonstrated impressive efficacy, with a median progression-free survival of 6.5 months and an ORR of 82% (Zuma-1 trial) (Zuma et al., 2017).
3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
This study's planned enrollment of 10 is below the median of 41 across 3,009 interventional studies indexed under Multiple Myeloma.
Browse Multiple Myeloma studies →Dr. Zaineb Akram is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria
Exclusion Criteria
1. Patients who will meet any of the following criteria will not be eligible to participate in the study.
Any other circumstances that would impair the ability of the participant to receive or tolerate the planned treatment at the site, to understand informed consent, or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
-
Exclusion Criteria:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6.2. Screening Phase During the Screening period, all participants will be asked to provide written consent for study participation and will be screened for study eligibility within 28 days before apheresis. Safety criteria that must be met before starting apheresis are presented in Section 8.1.1. If an assessment was performed as part of the participant's routine clinical evaluation and not specifically for this study, it does not need to be repeated after signed informed consent has been obtained, provided the assessments fulfill the study requirements and are performed within the specified timeframe before the first dose of study treatment. Retesting of abnormal screening values that lead to exclusion is allowed only once during the screening phase (to reassess eligibility). The last result obtained before apheresis will be used to determine eligibility. Subjects who do not meet all inclusion criteria or who meet an exclusion criterion may, at the discretion of the investigator,
Biological: CAR-T
CAR-T therapy will be given
Assess Safety /tolerability and feasibility of manufacturing and delivering the product
incidence/severity of AEs including CRS/ICANS (ASTCT grading), DLTs through Day +28
Time frame: From enrolment to 1 years after infusion of the product
Plan to share: Yes — IPD will be shared on request by email.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: after 31st December 2027 till 31st December 2028
Access criteria: Access will be given by requesting PI by email
Data sharing details ↗ · nibmtevents.com
Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.
Of 411 non-industry phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 18 months is below that.
Counting every sponsor, half of 504 studies reached it within 57 months; a quarter within 35 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr. Zaineb Akram